{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:40:06Z","timestamp":1744285206074,"version":"3.40.4"},"reference-count":52,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1517\/14656566.7.9.1221","type":"journal-article","created":{"date-parts":[[2006,5,30]],"date-time":"2006-05-30T11:03:55Z","timestamp":1148987035000},"page":"1221-1228","source":"Crossref","is-referenced-by-count":3,"title":["Ziprasidone in bipolar disorder"],"prefix":"10.1517","volume":"7","author":[{"given":"Marcio","family":"Versiani","sequence":"first","affiliation":[{"name":"Head Professor of Psychiatry and Director, Bipolar Disorders Program, Institute of Psychiatry, Federal University of Rio de Janeiro, R. Visconde de Piraj\u00e1 407 s.805, Rio de Janeiro, 22410-003, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2006,5,30]]},"reference":[{"volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000","key":"e_1_3_2_3_1","unstructured":"AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). American Psychiatric Association, Washington DC, USA (2000)."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0111"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00332-4"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.04.011"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.8.956"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.3.261"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0610"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.12.1322"},{"volume-title":"A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, Mass (Volume 1)","year":"1996","key":"e_1_3_2_12_1","unstructured":"The global burden of disease and injury series. In: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, Mass (Volume 1). CL Murra, AD Lopez (Eds), Harvard School of Public Health on behalf of the World Health Organization and the World Bank; Harvard University Press, Cambridge, MA, USA (1996)."},{"key":"e_1_3_2_13_1","first-page":"S80","volume":"11","author":"SAJATOVIC","year":"2005","unstructured":"SAJATOVIC M: Bipolar disorder: disease burden. Am. J. Manag. Care (2005) 11:S80-S84.","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2001.00059.x"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(03)00161-7"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00295-2"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.7.617"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00311-7"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0111"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.1.1"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0710"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1005"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.1.133"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(00)00162-2"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-4-12"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565020-00006"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900019842"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0111"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0116"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0502"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","volume":"275","author":"SEEGER","year":"1995","unstructured":"SEEGER TF, SEYMOUR PA, SCHMIDT AW et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. (1995) 275(1):101-113.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01188-8"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0102"},{"key":"e_1_3_2_34_1","first-page":"863","volume":"25","author":"PRAKASH","year":"1997","unstructured":"PRAKASH C, KAMEL A, GUMMERUS J et al.: Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. (1997) 25(7):863-872.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00151.x"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.004036"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00157.x"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00155.x"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00148.x"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/j.1875-9114.1998.tb03820.x","volume":"18","author":"HAMELIN","year":"1998","unstructured":"HAMELIN BA, ALLARD S, LAPLANTE L et al.: The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy (1998) 18(1):9-15.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000169068.34322.70"},{"key":"e_1_3_2_43_1","first-page":"S128","volume":"20","author":"DUNN","year":"2005","unstructured":"DUNN J, RAMEY T, GILLER E et al.: Efficacy and tolerability of ziprasidone in acute bipolar mania: 12 week double blind study. Eur. Psychiatry (2005) 20:(Suppl. 1):S128-P0305.","journal-title":"Eur. Psychiatry"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.07.008"},{"key":"e_1_3_2_45_1","first-page":"171S","volume":"57","author":"ZAJECKA","year":"2005","unstructured":"ZAJECKA J, MURRAY S, RAMEY T et al.: Efficacy of ziprasidone in dysphoric mania: analysis of 3 double-blind studies. Biol. Psychiatry (2005) 57(Suppl. 8):171S.","journal-title":"Biol. Psychiatry"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1981.01780260100011"},{"key":"e_1_3_2_47_1","first-page":"S128","volume":"20","author":"VERSIANI","year":"2005","unstructured":"VERSIANI M, KECK P, POTKIN G et al.: Efficacy and safety of ziprasidone in bipolar disorder: long-term data. Eur. Psychiatry (2005) 20(Suppl. 1):S128.","journal-title":"Eur. Psychiatry"},{"key":"e_1_3_2_48_1","first-page":"109S","volume":"57","author":"WARRINGTON","year":"2005","unstructured":"WARRINGTON L, POTKIN SG, ICE K et al.: Ziprasidone\u2019s long-term efficacy in subpopulations with bipolar mania. Biol. Psychiatry (2005) 57(Suppl. 1):109S.","journal-title":"Biol. Psychiatry"},{"key":"e_1_3_2_49_1","first-page":"43S","volume":"55","author":"WEISLER","year":"2004","unstructured":"WEISLER R, WARRINGTON L, DUNN J: Adjunctive ziprasidone in bipolar mania: short- and long-term data. Biol. Psychiatry (2004) 55(Suppl. 1):43S.","journal-title":"Biol. Psychiatry"},{"key":"e_1_3_2_50_1","volume-title":"158th American Psychiatric Association meeting","author":"WARRINGTON","year":"2005","unstructured":"WARRINGTON L, DUNN J, MANDEL F: Ziprasidone safety and tolerability in bipolar mania: review of trial data. 158th American Psychiatric Association meeting, Atlanta, GA, USA (2005). Poster."},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0109"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0101"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00235.x"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.7.9.1221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:10:04Z","timestamp":1744283404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.7.9.1221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,30]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1517\/14656566.7.9.1221"],"URL":"https:\/\/doi.org\/10.1517\/14656566.7.9.1221","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"type":"print","value":"1465-6566"},{"type":"electronic","value":"1744-7666"}],"subject":[],"published":{"date-parts":[[2006,5,30]]}}}